C&R RESEARCH INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,511 KRW | -0.33% |
|
-2.95% | +26.97% |
| Sales 2022 | 4.85TCr 3.48Cr 290.99Cr | Sales 2023 | 5.51TCr 3.96Cr 330.61Cr | Capitalization | 6.53TCr 4.69Cr 391.64Cr |
|---|---|---|---|---|---|
| Net income 2022 | 392.9Cr 28.21L 24Cr | Net income 2023 | 556.3Cr 39.94L 33Cr | EV / Sales 2022 | 1.22 x |
| Net cash position 2022 | 290.35Cr 20.85L 17Cr | Net cash position 2023 | 540.77Cr 38.83L 32Cr | EV / Sales 2023 | 1.09 x |
| P/E ratio 2022 |
15.6
x | P/E ratio 2023 |
11.9
x | Employees | 495 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 35.5% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.33% | ||
| 1 week | -2.95% | ||
| Current month | -13.41% | ||
| 1 month | -9.25% | ||
| 3 months | +24.77% | ||
| 6 months | +26.97% | ||
| Current year | +26.97% |
1 week
1 466.00
1 549.00
1 month
1 466.002 010.00
Current year
1 177.002 395.00
1 year
1 078.002 395.00
3 years
1 078.002 680.00
5 years
1 078.002 680.00
10 years
1 078.002 680.00
| Managers | Title | Age | Since |
|---|---|---|---|
Moon-Tae Yoon
CEO | Chief Executive Officer | 72 | 08/21/08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Moon-Tae Yoon
CEO | Chief Executive Officer | 72 | 08/21/08 |
Hong-In No
BRD | Director/Board Member | 64 | - |
Jung-Hee Park
BRD | Director/Board Member | 60 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1,511 | -0.33% | 528 855 |
| 25/24/25 | 1,516 | +0.53% | 381,241 |
| 24/24/24 | 1,508 | +1.55% | 314,546 |
| 21/24/21 | 1,485 | -1.26% | 358,678 |
| 20/24/20 | 1,504 | -0.86% | 252,080 |
End-of-day quote Korea S.E., June 26, 2024
More quotes
C&R Research Inc is a Korea-based company is mainly engaged in the clinical trial agency and drug development business. The Company is mainly engaged in the provision of comprehensive early-stage clinical services in the areas of medical writing, regulatory matters, data management, biostatistics and others. The Company is mainly engaged in the provision of consulting services including initial clinical development, clinical trial development, global clinical trial development and others. In addition, the Company is also engaged in the operation of clinical trial training center.
Calendar
12/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +26.97% | 6.14Cr | |
| +25.50% | 5.27TCr | |
| +37.49% | 3.9TCr | |
| -9.14% | 3.85TCr | |
| +28.00% | 3.04TCr | |
| -12.26% | 2.64TCr | |
| +10.46% | 2.61TCr | |
| +45.00% | 1.42TCr | |
| +32.34% | 1.26TCr | |
| -6.14% | 1.15TCr |
- Stock Market
- Equities
- A359090 Stock
